MACK - Merrimack Pharmaceuticals, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 589.98M
Enterprise Value 347.54M
Trailing P/E N/A
Forward P/E 1N/A
PEG Ratio (5 yr expected) 1N/A
Price/Sales (ttm)N/A
Price/Book (mrq)2.25
Enterprise Value/Revenue 3N/A
Enterprise Value/EBITDA 6-1.15

Trading Information

Stock Price History

Beta (3Y Monthly) 2.13
52-Week Change 318.87%
S&P500 52-Week Change 30.90%
52 Week High 37.50
52 Week Low 33.34
50-Day Moving Average 36.12
200-Day Moving Average 36.13

Share Statistics

Avg Vol (3 month) 360.42k
Avg Vol (10 day) 333.74k
Shares Outstanding 513.35M
Float 9.1M
% Held by Insiders 14.09%
% Held by Institutions 157.26%
Shares Short (Jul 31, 2019) 4565.47k
Short Ratio (Jul 31, 2019) 47.63
Short % of Float (Jul 31, 2019) 45.41%
Short % of Shares Outstanding (Jul 31, 2019) 44.24%
Shares Short (prior month Jun 28, 2019) 4572.83k

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 310.55
Trailing Annual Dividend Yield 3156.53%
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3Sep 5, 2019
Ex-Dividend Date 4Sep 6, 2019
Last Split Factor (new per old) 210/1
Last Split Date 3Sep 6, 2017

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2018
Most Recent Quarter (mrq)Jun 30, 2019

Profitability

Profit Margin 0.00%
Operating Margin (ttm)0.00%

Management Effectiveness

Return on Assets (ttm)-45.42%
Return on Equity (ttm)-88.16%

Income Statement

Revenue (ttm)N/A
Revenue Per Share (ttm)N/A
Quarterly Revenue Growth (yoy)N/A
Gross Profit (ttm)-48.97M
EBITDA -41.48M
Net Income Avi to Common (ttm)-45.1M
Diluted EPS (ttm)-1.86
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)39.9M
Total Cash Per Share (mrq)2.99
Total Debt (mrq)N/A
Total Debt/Equity (mrq)N/A
Current Ratio (mrq)8.61
Book Value Per Share (mrq)3.00

Cash Flow Statement

Operating Cash Flow (ttm)-57.53M
Levered Free Cash Flow (ttm)-37.25M